Persistent URL of this record https://hdl.handle.net/1887/104676
In Collections
This item can be found in the following collections:
Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
- All authors
- Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Nota, N.M.; Jager, A.; Velden, A.M.T. van der; Bos, M.M.E.M.; Linn, S.C.; Bosch, J. van den; Kroep, J.R.; Braun, J.J.; Haas, R.R. de; Smorenburg, C.H.; Graaf, H. de; Portielje, J.E.A.; M. los; Gooyer, D. de; Tinteren, H. van; E. boven; Dutch Breast Canc Trialists' Grp B
- Date
- 2013-05-20
- Journal
- Journal of Clinical Oncology
- Volume
- 31
- Issue
- 15